Protagonist Therapeutics (NASDAQ: PTGX) reported Q2 EPS of $2.29, $0.16 better than the analyst estimate of $2.13. Revenue for the quarter came in at $213.47 million versus the consensus estimate of $190.12 million.

For earnings history and earnings-related data on Protagonist Therapeutics (PTGX) click here.